Weehawken, NJ, United States of America

Linxiao Chen

USPTO Granted Patents = 4 

 

Average Co-Inventor Count = 7.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Location History:

  • Weehawken, NJ (US) (2019 - 2022)
  • Doylestown, PA (US) (2023)

Company Filing History:


Years Active: 2019-2023

Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: Inventor Linxiao Chen: Pioneering Anti-Galectin-9 Antibodies

Introduction

Linxiao Chen is an esteemed inventor based in Weehawken, NJ, whose research and innovations have led to the establishment of four significant patents. His work primarily focuses on anti-Galectin-9 antibodies, which hold great potential in the field of medical diagnostics and treatment.

Latest Patents

Among Linxiao Chen's latest contributions are patented methods associated with anti-Galectin-9 antibodies. These antibodies are designed to inhibit a signaling pathway mediated by Galectin-9 or to eliminate pathologic cells that express this protein. Such innovations may be crucial for diagnosing and treating diseases related to Galectin-9, including various autoimmune diseases and solid tumors. The potential applications of these antibodies are expansive, paving the way for advancements in targeted therapies and personalized medicine.

Career Highlights

Throughout his career, Linxiao Chen has worked with reputable institutions such as New York University and Puretech Health, LLC. His endeavors in these organizations have not only contributed to his professional growth but have also significantly influenced the fields of biotechnology and pharmaceuticals.

Collaborations

Linxiao Chen has collaborated with distinguished colleagues, including Shohei Koide and George Miller. These partnerships have enriched his research and amplified the impact of his inventions in the scientific community.

Conclusion

Linxiao Chen's work on anti-Galectin-9 antibodies exemplifies innovation in the realm of biomedicine. With four patents under his belt, he continues to push the boundaries of research, ultimately aiming to improve treatment options for diseases linked to Galectin-9. His contributions signify an essential stride toward advancing healthcare solutions and enhancing patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…